Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2010

Dickens Nicholas J, Walker Brian A, Leone Paola E, Johnson David C, Brito José L, Zeisig Athanasia, Jenner Matthew W, Boyd Kevin D, Gonzalez David, Gregory Walter M, Ross Fiona M, Davies Faith E, Morgan Gareth J

Abstract excerpt

PURPOSE: Myeloma is a clonal malignancy of plasma cells. Poor-prognosis risk is currently identified by clinical and cytogenetic features. However, these indicators do not capture all prognostic information. Gene expression analysis can be used to identify poor-prognosis patients and this can be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Homozygote

Share to Multiple Myeloma

Share to Oligonucleotide Array Sequence Analysis

Share to Sequence Deletion

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 20215539
DOI: 10.1158/1078-0432.CCR-09-2831
PMCID: PMC2841345

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20215539-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.PMID 20215539Read ↗

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.Semantic proximity Read ↗

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.Semantic proximity Read ↗

Gene expression profiling defines a high-risk entity of multiple myeloma.Semantic proximity Read ↗

A gene expression signature based on cell-death related gene expression in multiple myelomaSemantic proximity Read ↗

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisSemantic proximity Read ↗

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic markerSemantic proximity Read ↗

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical useSemantic proximity Read ↗

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.Semantic proximity Read ↗

Identification of mutation gene prognostic biomarker in multiple myeloma through gene panel exome sequencing and transcriptome analysis in Chinese population.Semantic proximity Read ↗

Genomic analysis of high-risk smoldering multiple myeloma.Semantic proximity Read ↗

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.Semantic proximity Read ↗

Plasma Cell Enrichment and New Genomic Approaches in Multiple Myeloma: A Scoping ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.